John Lepping

Director at Linnaeus Therapeutics

Capital raised by Linnaeus Therapeutics

$6.3M+$5.0M latest round

5 Form D filings · first filed Aug 2025 · Haddonfield, NJ

CURRENT ROLE: Director
SECTOR: Biotechnology
COMPANY FILINGS: 5
TEAM ON FILE: 4
FOUNDED: —
30D INTEREST: 4 ↗

Career

1 company on file

Linnaeus TherapeuticsBiotechnology · Haddonfield, NJsince Aug 2025

Director

Listed on Linnaeus Therapeutics's Form D filings

Company filings

via EDGAR · Form D for Linnaeus Therapeutics5

DateCompanyFormAmountRole on filing

Feb 17, 2026Linnaeus TherapeuticsForm D/A+$5.0M—

Form D/AFeb 17, 2026 · Linnaeus Therapeutics+$5.0Mnot a signer

Feb 17, 2026Linnaeus TherapeuticsForm D/A+$4.9M—

Form D/AFeb 17, 2026 · Linnaeus Therapeutics+$4.9Mnot a signer

Feb 17, 2026Linnaeus TherapeuticsForm D/A+$4.8M—

Form D/AFeb 17, 2026 · Linnaeus Therapeutics+$4.8Mnot a signer

Feb 17, 2026Linnaeus TherapeuticsForm D+$4.5M—

Form DFeb 17, 2026 · Linnaeus Therapeutics+$4.5Mnot a signer

Aug 19, 2025Linnaeus TherapeuticsForm D+$1.3M—

Form DAug 19, 2025 · Linnaeus Therapeutics+$1.3Mnot a signer

Overview

Last filing Feb 17, 2026

John Lepping is on file as Director at Linnaeus Therapeutics in Haddonfield, NJ. Linnaeus Therapeutics has 5 Form D filings on record, $6.3M raised in total.

Teammates

Linnaeus Therapeutics · 3

Anthony GruzdisAttorney-in-factSigner Mariel J. GilettoAttorney-in-factSigner Michael PoiselDirector

Products

Linnaeus Therapeutics · 1

LNS8801Small-Molecule Therapeutic

LNS8801 is an orally administered, small-molecule agonist of the G protein-coupled estrogen receptor (GPER). It is being developed for cancer treatment and functions by rapidly depleting c-Myc protein levels, leading to antitumor activity and demonstrating target engagement in clinical trials.